First-Line Treatment Strategies in IMDC Favourable-Risk Metastatic Clear Cell Renal Cell Carcinoma.

Oncol Res · 2026 · PMC13397365 · PMID 42500582

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

IO+TKI doublets have not improved mOS over TKI monotherapy in favourable-risk disease [ 23 ], and updated CheckMate 214 data show a nonsignificant trend towards improved mOS with IO+IO versus TKI [ 21 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.